Target-activated prodrugs (TAPs) for the autoregulated inhibition of MMP12

ACS Medicinal Chemistry Letters

Volumn 3, Issue 8, 2012, Pages 653-657

  Cobos Correa, Amanda ^a,b   Stein, Frank ^a   Schultz, Carsten ^a,b,c  

^a EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c German Center for Lung Research   (Germany)

Author keywords

inflammation; inhibitors; MMP; prodrug; proteases

Indexed keywords

CARBOXYLIC ACID; COLLAGENASE 3; MACROPHAGE ELASTASE; METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; PRODRUG; SULFONAMIDE; ZINC ION;

ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG STABILITY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME KINETICS; HYDROLYSIS; IC 50; IN VITRO STUDY; MOLECULAR RECOGNITION; PH; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 84864986001     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml3001193     Document Type: Article

References (24)

1. Turk, B. Targeting proteases: Successes, failures and future prospects Nat. Rev. Drug Discovery 2006, 5 (9) 785-799 (Pubitemid 44323703)
2. Belaaouaj, A.; Shipley, J. M.; Kobayashi, D. K.; Zimonjic, D. B.; Popescu, N.; Silverman, G. A.; Shapiro, S. D. Human macrophage metalloelastase. Genomic organization, chromosomal location, gene linkage, and tissue-specific expression J. Biol. Chem. 1995, 270 (24) 14568-14575
3. Lagente, V. L.; Le Quement, C.; Boichot, E. Macrophage metalloelastase (MMP-12) as a target for inflammatory respiratory diseases Expert Opin. Ther. Targets 2009, 13 (3) 287-295
4. Uttamchandani, M. W.; Wang, J.; Li, J.; Hu, M.; Sun, H.; Chen, K. Y.; Liu, K.; Yao, S. Q. Inhibitor fingerprinting of matrix metalloproteases using a combinatorial peptide hydroxamate library J. Am. Chem. Soc. 2007, 129 (25) 7848-7858 (Pubitemid 46998183)
5. Hu, J.; Van den Steen, P. E.; Sang, Q. X.; Opdenakker, G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases Nat. Rev. Drug Discovery 2007, 6 (6) 480-498 (Pubitemid 47064570)
6. Coussens, L. M.; Fingleton, B.; Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations Science 2002, 295 (5564) 2387-2392 (Pubitemid 34270240)
7. Tu, G.; Xu, W.; Huang, H.; Li, S. Progress in the development of matrix metalloproteinase inhibitors Curr. Med. Chem. 2008, 15 (14) 1388-1395 (Pubitemid 351997789)
8. Skiles, J. W.; Gonnella, N. C.; Jeng, A. Y. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors Curr. Med. Chem. 2001, 8 (4) 425-474 (Pubitemid 32409788)
9. Li, X.; Wu, J. F. Recent developments in patent anti-cancer agents targeting the matrix metalloproteinases (MMPs) Recent Pat. Anticancer Drug Discovery 2010, 5 (2) 109-141
10. Overall, C. M.; Kleifeld, O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy Br. J. Cancer 2006, 94 (7) 941-946
11. Kline, T.; Torgov, M. Y.; Mendelsohn, B. A.; Cerveny, C. G.; Senter, P. D. Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and -9 Mol. Pharmaceutics 2004, 1 (1) 9-22
12. Milo, L. J. J.; Lai, J. H.; Wu, W.; Liu, Y.; Maw, H.; Li, Y.; Jin, Z.; Shu, Y.; Poplawski, S. E.; Wu, Y.; Sanford, D. G.; Sudmeier, J. L.; Bachovchin, W. W. Chemical and biological evaluation of dipeptidyl boronic acid proteasome inhibitors for use in prodrugs and pro-soft drugs targeting solid tumors J. Med. Chem. 2011, 54 (13) 4365-4377
13. Pickett, S. D.; Green, D. V. S.; Hunt, D. L.; Pardoe, D. A.; Hughes, I. Automated Lead Optimization of MMP-12 Inhibitors Using a Genetic Algorithm ACS Med. Chem. Lett. 2011, 2 (1) 28-33
14. Rouffet, M.; Denhez, C.; Bourguet, E.; Bohr, F.; Guillaume, D. In silico study of MMP inhibition Org. Biomol. Chem. 2009, 7, 3817-3825
15. Dragoni, E.; Calderone, V.; Fragai, M.; Jaiswal, R.; Luchinat, C.; Nativi, C. Biotin-Tagged Probes for MMP Expression and Activation: Design, Synthesis, and Binding Properties Bioconjugate Chem. 2009, 20 (4) 719-727
16. Agrawal, A.; Romero-Perez, D.; Jacobsen, J. A.; Villarreal, F. J.; Cohen, S. M. Zinc-binding groups modulate selective inhibition of MMPs ChemMedChem 2008, 3 (5) 812-20
17. Summers, J. B.; Gunn, B. P.; Mazdiyasni, H.; Goetze, A. M.; Young, P. R.; Bouska, J. B.; Dyer, R. D.; Brooks, D. W.; Carter, G. W. In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase J. Med. Chem. 1987, 30 (11) 2121-2126 (Pubitemid 18046074)
18. Puerta, D. T.; Cohen, S. M. A bioinorganic perspective on matrix metalloproteinase inhibition Curr. Top. Med. Chem. 2004, 4 (15) 1551-1573 (Pubitemid 39662664)
19. Devel, L.; Rogakos, V.; David, A.; Makaritis, A.; Beau, F.; Cuniasse, P.; Yiotakis, A.; Dive, V. Development of selective inhibitors and substrate of matrix metalloproteinase-12 J. Biol. Chem. 2006, 281 (16) 11152-11160 (Pubitemid 43855540)
20. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. Design and therapeutic application of matrix metalloproteinase inhibitors Chem. Rev. 1999, 99 (9) 2735-2776
21. Verma, R. P.; Hansch, C. Matrix metalloproteinases (MMPs): Chemical-biological functions and (Q)SARs Bioorg. Med. Chem. 2007, 15 (6) 2223-2268 (Pubitemid 46240907)
22. Vaccarino, A. L.; Paul, D.; Mukherjee, P. K.; Rodríguez de Turco, E. B.; Marcheselli, V. L.; Xu, L.; Trudell, M. L.; Minguez, J. M.; Matía, M. P.; Sunkel, C.; Alvarez-Builla, J.; Bazan, N. G. Synthesis and in vivo evaluation of non-hepatotoxic acetaminophen analogs Bioorg. Med. Chem. 2007, 15 (5) 2206
23. Cobos-Correa, A.; Trojanek, J. B.; Diemer, S.; Mall, M. A.; Schultz, C. Membrane-bound FRET probe visualizes MMP12 activity in pulmonary inflammation Nat. Chem. Biol. 2009, 5 (9) 628-630
24. Larsen, J. D.; Bundgaard, H.; Lee, V. H. L. Prodrug forms for the sulfonamide group. II. Water-soluble amino acid derivatives of N-methylsulfonamides as possible prodrugs Int. J. Pharm. 1988, 41 (1-3) 103-110